Emanuele Crupi

Emanuele Crupi

Auto-generated profile, based on publicly available information

Emanuele Crupi

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
GBGiuseppe Basile
Giuseppe Basile
MBMarco Bandini
Marco Bandini
EGEwan A. Gibb
Ewan A. Gibb
JRJeffrey Ross
Jeffrey Ross
DRDaniele Raggi
Daniele Raggi
Andrea NecchiAndrea Necchi
Andrea Necchi
Purpose: The PURE-01 study (NCT02736266) pioneered the neoadjuvant immune-checkpoint inhibitor (ICI) therapy before radical cystectomy (RC) in patients with muscle-invasive urothelial bladder carcinoma (MIBC). We herein present the survival outcomes after a median follow-up of three years. Patients and Methods: The intention-to-treat (ITT) population included 155 patients. Event-free survival (EFS) was defined as the time from pembrolizumab initiation until radiographic disease progression precluding RC, initiation of neoadjuvant chemotherapy, recurrence after RC, or death. Further outcomes were recurrence-free survival (RFS) post-RC and overall survival (OS). Multivariable Cox regression analyses for EFS were performed. Kaplan–Meier analyses compared EFS outcomes according with baseline programmed cell-death-ligand-1 (PD-L1) combined positive score (CPS) and according to the molecular subtypes. Results: After a median (interquartile range, IQR) follow-up of 39 (30–47) months, 36-month EFS and OS were 74.4% [95% confidence interval (CI), 67.8–81.7] and 83.8% (95% CI, 77.8–90.2) in the ITT population, respectively. Overall, 143 (92.3%) patients underwent RC. Within the cohort of patients who did not receive additional chemotherapy (N = 125), 36-month RFS was 96.3% (95% CI, 91.6–100) for patients achieving a ypT0N0, 96.1% (95% CI, 89–100) for ypT1/a/isN0, 74.9% (95% CI, 60.2–93) for ypT2–4N0, and 58.3% (95% CI, 36.2–94.1) for ypTanyN1–3 response. EFS was significantly stratified among PD-L1 tertiles (lower tertile: 59.7% vs. medium tertile: 76.7% vs. higher tertile: 89.8%, P = 0.0013). The claudin-low and basal/squamous subtypes displayed the lowest rates of events. Conclusions: At a median follow-up of three years, PURE-01 results further confirm the sustained efficacy of neoadjuvant pembrolizumab before RC. PD-L1 expression was the strongest predictor of sustained response post-RC.

15 August 2025 in Nature Reviews Urology
Verified
Journal Article
Closed access
DRDaniele Raggi
Daniele Raggi
ECEmanuele Crupi
Emanuele Crupi
FPFilippo Pederzoli
Filippo Pederzoli
AMAlberto Martini
Alberto Martini
ABAlberto Briganti
Alberto Briganti
MGMatthew D. Galsky
Matthew D. Galsky

1 December 2024 in Radiology
Verified
Journal Article
Closed access
GBGiorgio Brembilla
Giorgio Brembilla
GBGiuseppe Basile
Giuseppe Basile
MCMichele Cosenza
Michele Cosenza
FGFrancesco Giganti
Francesco Giganti
APAndrea Del Prete
Andrea Del Prete
Francesco De CobelliFrancesco De Cobelli
Francesco De Cobelli
Neoadjuvant chemotherapy Vesical Imaging Reporting and Data System scores were accurate and reproducible for the assessment of muscle-invasive bladder cancer response to neoadjuvant immunotherapy.

16 October 2023 in BJU International
Verified
Journal Article
Closed access
ANAndrea Necchi
Andrea Necchi
GBGiuseppe Basile
Giuseppe Basile
EGEwan A. Gibb
Ewan A. Gibb
DRDaniele Raggi
Daniele Raggi
GCGiuseppina Calareso
Giuseppina Calareso
GBGiorgio Brembilla
Giorgio Brembilla

1 December 2024 in JCO Precision Oncology
Verified
Journal Article
Closed access
ECEmanuele Crupi
Emanuele Crupi
TPTiago Costa de Padua
Tiago Costa de Padua
LMLaura Marandino
Laura Marandino
GFGiuseppe Fallara
Giuseppe Fallara
FPFilippo Pederzoli
Filippo Pederzoli
DRDaniele Raggi
Daniele Raggi
PURPOSE: Aberrant expression of nectin-4 (N4) has been observed in several malignancies emerging as new target for antibody-drug conjugates, especially in urothelial carcinoma of the bladder (UBC). Limited data on N4 positivity in nonurothelial genitourinary (GU) cancers are available. This systematic-review aimed to investigate N4 positivity among GU malignancies. METHODS: A systematic literature review was performed on March 2023 using PubMed, MEDLINE, and Embase databases according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Protocol was amended to incorporate a new updated search on March 2024. RESULTS: Twenty-five studies evaluating N4 positivity in GU tumors were included, 14 on UBC, three on upper tract urothelial carcinoma (UTUC), six on histologic subtypes (HS) and divergent histology of the bladder, one on papillary renal cell carcinoma (pRCC), one in chromophobe RCC (chRCC), two on penile cancer, one in prostate cancer (PCa). Among UBC, stratifying per stage N4 positivity was higher in metastatic (weighted mean [WM], 90.8; range, 59.6-100) and in non–muscle-invasive (WM, 87.4; range, 86.7-88.3) than in muscle-invasive UC (WM, 83.1; range, 68.2-100). The N4 positivity of UBC was higher than UTUC (WM, 62.9; range, 44.4-65.7). Immunohistochemistry N4 positivity was reported to be lower in non-UC malignancies, including pRCC (WM, 44.1; range, 44.1-44.1), HS (WM, 63.5; range, 0-100), PCa (WM0; range, 0-0), chRCC (WM, 18.5; range, 18.5-18.5), and penile cancer (WM, 86.5; range, 61.4-98.3), compared with UBC overall (WM, 87.1; range, 59.6-100). CONCLUSION: Non-UC malignancies seem to have a lower N4 positivity rate than UC. N4 positivity in bladder cancer appears to vary according to stage and presence of HS. The predictive and prognostic role of N4 must be further characterized in larger and prospective studies.

20 September 2024 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
MRMoritz Johannes Reike
Moritz Johannes Reike
DRDaniele Raggi
Daniele Raggi
CMChiara Mercinelli
Chiara Mercinelli
ACAntonio Cigliola
Antonio Cigliola
VTValentina Tateo
Valentina Tateo
Andrea NecchiAndrea Necchi
Andrea Necchi